Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Shinichi Makita1 | Go Yamamoto2 | Dai Maruyama1 | Yuki Asano-Mori2 | Daisuke Kaji2 | Revathi Ananthakrishnan3 | Ken Ogasawara3 | Lara Stepan3 | Claudia Schusterbauer4 | Nils Rettby4 | Jens Hasskarl4 | Koji Izutsu1

1National Cancer Center Hospital, Tokyo, Japan
2Toranomon Hospital, Tokyo, Japan
3Bristol Myers Squibb, Princeton, New Jersey, USA
4Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland

Correspondence
Koji Izutsu, National Cancer Center Hospital, Tokyo, Japan.
Email: kizutsu@ncc.go.jp

Funding information
Bristol-Myers Squibb; Celgene

Abstract
The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This analysis assessed safety and efficacy of liso-cel in Japanese patients with relapsed or refractory (R/R) aggressive large B-cell lymphoma (LBCL) in Cohort 3 of TRANSCEND WORLD (NCT03484702). Liso-cel (100×10^6 total CAR+ T cells) was administered 2–7 days after lymphodepletion. The primary efficacy endpoint was objective response rate (ORR; Lugano 2014 criteria) assessed by an independent review committee. Fourteen patients were enrolled; 10 received liso-cel infusion (median time to liso-cel availability, 23 days) and were evaluable at data cutoff (median follow-up, 12.5 months). Grade ≥3 treatment-emergent adverse events were neutropenia (90%), leukopenia (80%), anemia (70%), and thrombocytopenia (70%). All-grade cytokine release syndrome (CRS) was observed in 50% of patients, though no grade ≥3 CRS events were reported. Grade 1 neurological events occurred in 1 patient but were resolved without any intervention. Prolonged cytopenia (grade ≥3 at day 29) was reported for 60% of patients. The ORR was 70%, and complete response rate was 50%. The median duration of response was 9.1 months (95% confidence interval [CI], 2.1—not reached), and overall survival was 14.7 months (95% CI, 1.7—not reached). One patient diagnosed with central nervous system involvement after screening but before liso-cel infusion, responded to liso-cel. Liso-cel demonstrated meaningful efficacy and a manageable safety profile in Japanese patients with R/R LBCL.

KEYWORDS
Japanese patients, large B-cell lymphoma, lisocabtagene maraleucel, non-Hodgkin lymphoma, relapsed/refractory

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Diffuse large B-cell lymphoma (DLBCL) accounts for one-third of all non-Hodgkin lymphomas (NHL) in Japan. Although the introduction of the anti-CD20 monoclonal antibody rituximab has improved the prognosis of patients with DLBCL in recent decades, nearly 40% of patients experience relapsed and/or refractory (R/R) disease after rituximab-containing first-line chemotherapy. Salvage cytotoxic chemotherapy followed by high-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care in patients with first relapse or refractory (R/R) DLBCL. However, this strategy is limited to relatively younger patients (usually 65 years or younger) with adequate organ function and chemotherapy-sensitive disease. Once the disease becomes refractory, it is difficult to manage it with conventional cytotoxic chemotherapies. A multinational retrospective study of outcomes in North America and Europe reported a median overall survival (OS) of 6.3 months in patients with refractory DLBCL; similar outcomes (7 months) have been reported in the Japanese population.

Several novel agents have been developed for patients with R/R large B-cell lymphoma (LBCL), including DLBCL. Among them, anti-CD19 chimeric antigen receptor (CAR) T-cell therapies are considered one of the most promising treatment options for this population. The CD19-directed autologous CAR T-cell product, lisocabtagene maraleucel (liso-cel), is administered as a sequential infusion of equal target doses of CD8+ and CD4+ CAR+ T cells. Liso-cel production involves purifying CD8+ and CD4+ cells separately before activation and transduction followed by T-cell-specific activation and expansion, which reduces the variability of CD3 T-cell frequencies, relative to leukapheresis.

In animal models, a defined composition of CD8+ and CD4+ CAR+ T cells demonstrated better expansion and was associated with improved efficacy compared with treatment using either T-cell component separately. Administering a defined composition of CD8+ and CD4+ CAR+ T cells results in a more uniform CAR T-cell product and may allow the identification of factors associated with CAR T-cell kinetics and outcomes. Liso-cel consists of autologous T cells transduced with a lentiviral vector encoding a CAR that incorporates an anti-CD19 single-chain variable fragment, a 4-1BB costimulatory motif, and a CD3ζ T-cell activation domain. Growing evidence from preclinical studies suggests that the 4-1BB costimulatory domain may enhance the persistence and safety of CAR T-cell therapy.

Liso-cel safety and efficacy were assessed in the multicenter, multicohort, seamless design, pivotal United States study, TRANSCEND NHL 001 (NCT02631044). In that study, liso-cel demonstrated rapid and durable responses in patients with R/R LBCL. The objective of this study (TRANSCEND WORLD [NCT03484702]) was to characterize the safety and efficacy of liso-cel treatment in non-US patients with R/R LBCL; here we report the results of Cohort 3, which only enrolled patients in Japan.

2 | MATERIALS AND METHODS

2.1 | Study design and patient population

TRANSCEND WORLD is a single-arm, open-label, multinational, multicohort, phase 2 study (Appendix S1). Results from Cohort 3 are reported here and follow-up in this cohort is ongoing.

Adult Japanese patients who met the following criteria were eligible for the study: R/R LBCL (DLBCL de novo or transformed follicular lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology, or follicular lymphoma grade 3B), adequate organ function, and either receipt of ≥2 prior lines of therapy and Eastern Cooperative Oncology Group performance status (ECOG PS) score ≤1 or receipt of 1 prior line of therapy and not eligible for transplantation with ECOG PS ≤2. Prior treatment with an anti-CD20 antibody and anthracycline was required. Secondary central nervous system (CNS) lymphoma was allowed.

We adhered to the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Before screening, written informed consent was obtained from each patient. An independent ethics committee at each site reviewed and approved the protocol before initiating the study.

Patients underwent leukapheresis to collect autologous peripheral blood mononuclear cells for the manufacture of liso-cel. Target processing blood volume was determined by the number of peripheral blood lymphocytes. Patients with a lymphocyte count ≥500/μL had processing volumes of 7 L, while patients with lymphocytes <500/μL had processing volumes of 12 L. After leukapheresis, fresh leukapheresate was shipped to the manufacturing site without cryopreservation. All CAR T-cell products in this study were manufactured at the sponsor’s manufacturing facility in Bothell, WA, USA. Leukapheresis material was immunomagnetically selected for CD8+ and CD4+ T cells, which were then independently activated, transduced with the liso-cel CAR construct, and expanded in order to obtain the cell numbers required for infusion at the target doses of CD8+ and CD4+ CAR+ T cells. Both the CD8+ and CD4+ CAR+ T-cell components were required to meet...
quality specifications prior to release for infusion and to be considered liso-cel. However, patients could receive a nonconforming CAR T-cell product (i.e., one of the CD8 or CD4 cell components did not meet one of the requirements to be considered liso-cel).

Bridging chemotherapy (systemic and/or radiation) was allowed at the discretion of the treating clinician during the liso-cel manufacturing period. Patients had to continue to meet eligibility criteria for lymphodepleting chemotherapy (LDC)/infusion, including having PET-positive disease before proceeding to study treatment.

LDC comprising fludarabine (30 mg/m²) and cyclophosphamide (300 mg/m²) was administered intravenously daily for 3 days once the liso-cel product had become available. Liso-cel (target dose of 100×10⁶ total CAR⁺ T cells) was administered 2–7 days after LDC.

### 2.2 Study assessments

The primary endpoint was the objective response rate (ORR, defined as the proportion of patients achieving a complete response [CR] or partial response [PR]) as assessed by an independent review committee (IRC) per the Lugano 2014 PET-computed tomography (CT) criteria; secondary endpoints included safety, CR rate, duration of response (DOR), progression-free survival (PFS), and OS. The cellular kinetic profile, incidence of B-cell aplasia, and laboratory abnormalities were also explored. DOR was defined as the time from first response (CR or PR) to disease progression or death. PFS was defined as the time from liso-cel infusion to disease progression or death. OS was defined as the time from liso-cel infusion to death. Adverse events (AE), laboratory abnormalities, vital signs, and other safety measures were collected at protocol-defined time points. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03. Neurological events (NE) were defined as investigator-identified neurological AEs related to liso-cel and were graded using NCI CTCAE v4.03. Lee 2014 criteria were used to grade cytokine release syndrome (CRS). Investigators were trained in the recognition, management, and grading of CRS and NEs, including the importance of excluding other causes of fever or neurological symptoms. Suspected cases of CRS and NEs were managed according to the recommended treatment algorithms (Appendix S1). Treatment of CRS included tocilizumab (not to exceed 3 doses in 24 h and 4 total doses) and increasing dexamethasone as indicated. Treatment of NE included dexamethasone, with dose and frequency adjusted on grade and response to treatment. Recommendations for the highest-grade event were used if concurrent CRS and NE were present. Prolonged cytopenia was defined as laboratory-assessed neutropenia, thrombocytopenia, or anemia of grade ≥ 3 not resolved by study day 29. Cellular kinetics, based on quantitative polymerase chain reaction, were assessed as described previously. B-cell aplasia (defined as < 3% CD19⁺ peripheral blood lymphocytes) was analyzed by T-cell, B-cell, and natural killer cell detection assay.

### 2.3 Statistical analysis

This primary efficacy analysis for Cohort 3 was planned to initiate after 10 patients were treated with liso-cel and followed for at least 3 months. Statistical analyses were based on the following analysis sets: liso-cel-treated set (all patients who received liso-cel; primary efficacy and safety analysis set), efficacy-evaluable set (all patients who received liso-cel, had baseline assessment and with ≥ 1 valid post-liso-cel disease assessment), and leukapheresed set (all patients who underwent leukapheresis). For binary endpoints, the frequency distribution (n, %) and two-sided exact 95% confidence intervals (CI) were calculated. ORR was calculated with a two-sided 95% exact Clopper–Pearson CI. Time-to-event endpoints, such as PFS, utilized Kaplan–Meier product limit methodology to estimate the survivorship function, and medians with a two-sided 95% CI were calculated.

### 2.4 Data sharing statement

Bristol Myers Squibb policy on data sharing may be found at [https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html](https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html).

### 3 RESULTS

#### 3.1 Patient demographics

As of the June 19, 2020, data cutoff for this primary analysis, 14 patients in Cohort 3 underwent leukapheresis for the manufacture of CAR⁺ T cells (Figure 1). Two patients did not receive CAR⁺ T cells: 1 was no longer eligible for treatment because of deep vein thrombosis and 1 because of a manufacturing failure. Two patients received a nonconforming CAR⁺ T-cell product (i.e., release specification criteria for liso-cel not met, but product considered safe for infusion). For the 10 patients who received liso-cel, the median turnaround time (time from leukapheresis to product availability) was 23 (range, 21–33) days. The median study follow-up for the 10 patients who received liso-cel infusion and were evaluable for both safety and
efficacy at the data cutoff was 12.5 months. Follow-up is ongoing.

Table 1 shows characteristics at baseline of the 10 patients who received liso-cel. Median age was 57 (range, 47–73) years and 3 patients were aged ≥ 65 years. Patients were heavily pretreated, with a median of 3 (range, 1–9) prior lines of systemic therapy; 7 patients had refractory disease (defined as less than a CR to last therapy) and 3 had relapsed after initially responding to their last prior therapy. Two patients had received prior auto-HSCT. Bridging therapy was administered to all 10 patients at the investigator’s discretion (Table S1). The histologic subgroups included DLBCL not otherwise specified (n = 9, of which n = 3 had transformed follicular lymphoma) and follicular lymphoma grade 3B (n = 1). This cohort included the first report of a patient in Japan with DLBCL and secondary CNS lymphoma (diagnosed after screening) treated with CAR T-cell therapy.

### 3.2 Safety

The most common any-grade treatment-emergent AEs (TEAE) were neutropenia (90%), thrombocytopenia (90%), leukopenia (90%), anemia (80%), CRS (50%), fatigue (40%), hypofibrinogenemia (40%), and hypogammaglobulinemia (20%; all were grade 1 or 2). Grade ≥3 TEAEs were neutropenia (90%), leukopenia (80%), anemia (70%), and thrombocytopenia (70%) (Table 2). No other severe TEAEs were reported. Severe thrombocytopenia generally began at post-infusion day 15 (Figure S1). One patient, who had very rapid progressive disease, experienced a grade 5 TEAE of multiple organ dysfunction syndrome that was deemed not related to liso-cel. Among the 10 patients, 5 experienced any-grade CRS (3 grade 1; 2 grade 2) and 1 developed grade 1 NEs. No grade ≥3 CRS or NEs were reported.

| Characteristic | Liso-cel-treated patients (N = 10) |
|---------------|----------------------------------|
| Age, year     |                                  |
| Median (range)| 57 (47–73)                       |
| ≥65, n (%)    | 3 (30)                           |
| Male, n (%)   | 6 (60)                           |
| NHL subtype, n (%) |                  |
| DLBCL NOS     | 9 (90)                           |
| tFL           | 3 (30)                           |
| HGBCL         | 0                                |
| FL3B          | 1 (10)                           |
| Confirmed secondary CNS lymphoma at screening, n (%) | 0 |
| ECOG PS score before LDC, n (%) |                  |
| 0             | 6 (60)                           |
| 1             | 4 (40)                           |
| Prior therapy, n (%) |                          |
| Prior lines of therapy, median (range), n | 3 (1–9)                |
| Received prior HSCT | 2 (20)                     |
| Refractory to last therapy | 7 (70)                     |
| Relapsed after last therapy | 3 (30)                     |
| LDH ≥500 U/L before LDC, n (%) | 2 (20)                     |
| SPD ≥50 cm² before LDC, n (%) | 2 (20)                     |
| Received bridging therapy, n (%) | 10 (100)                   |

Abbreviations: CAR, chimeric antigen receptor; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL3B, follicular lymphoma grade 3B; GCB, germinal center B cell; HGBCL, high-grade B-cell lymphoma; HSCT, hematopoietic stem cell transplantation; LDC, lymphodepleting chemotherapy; LDH, lactate dehydrogenase; liso-cel, lisocabtagene maraleucel; N/A, not applicable; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; SPD, sum of the product of perpendicular diameters; tFL, transformed follicular lymphoma.
(Table 3). Of the 4 patients with reported hypofibrinogenemia, 3 experienced grade 1 or 2 CRS and one patient had a grade 2 NE. One patient experienced hemorrhage (grade 2) after a needle biopsy and one patient received a plasma transfusion. No severe bleeding events were reported.

Median times to CRS onset and resolution were 3 (range, 2–9) and 4 (range 1–5) days, respectively. In the patient who developed NEs, time to NE onset and resolution were 4 days and 3 days, respectively. Two patients received tocilizumab for CRS management (1 grade 1, and 1 grade 2); 1 patient experienced CRS (grade 2) and NEs (grade 1) and received tocilizumab and corticosteroids for symptom management. Prolonged cytopenia was reported in 60% of patients. One patient (10%) experienced a grade 2 infection.

### 3.3 Efficacy

All 10 liso-cel-treated patients were evaluable for response and were included in the efficacy evaluations. The ORR by IRC was 70%. CR and PR rates were 50% and 20%, respectively (Table 4). Four patients achieved a CR on day 29; 1 patient experienced a PR on day 29, which later deepened to a CR. Three patients did not respond to liso-cel and had progressive disease. The median DOR was 9.1 months (95% CI, 2.1—not reached [NR]), median PFS was 6.3 months (95% CI, 0.6—NR), and median OS was 14.7 months (95% CI, 1.7—NR). Of the 5 patients who achieved a best overall response of CR, 3 continued to maintain this response at the data cutoff date (Figure 2). A total of 5 liso-cel-treated patients have died due to disease progression and/or medical complications considered unrelated to liso-cel treatment.

### 3.4 Cellular kinetics

Among 10 patients evaluable for cellular kinetic analyses, median time to CAR T-cell peak expansion was 12 days, median maximum expansion was 46,562 copies/μg, and median area under the curve from 0 to 28 days post-infusion was 398,124 day×copies/μg (Figure 3). There were no apparent differences in cellular kinetics observed between responders and nonresponders (Figure S2). CAR T cells showed long-term persistence in 71% of evaluable patients (n = 5/7) at 6 months and in 100% of evaluable patients (n = 2/2) at 1 year.

---

**Table 2** Patient incidence of TEAEs

| Parameter                        | Liso-cel-treated patients (N = 10) |
|----------------------------------|-----------------------------------|
| Patients with TEAEs, n (%)       |                                   |
| Any TEAE                         | 10 (100)                          |
| Grade 3                          | 1 (10)                            |
| Grade 4                          | 7 (70)                            |
| Grade 5                          | 1 (10)                            |
| Any liso-cel-related TEAE, n (%) | 8 (80)                            |
| Grade 3                          | 2 (20)                            |
| Grade 4                          | 5 (50)                            |
| Grade 5                          | 0                                 |
| Grade 3/4 TEAEs, n (%)           |                                   |
| Neutropenia                      | 9 (90)                            |
| Leukopenia                       | 8 (80)                            |
| Anemia                           | 7 (70)                            |
| Thrombocytopenia                 | 7 (70)                            |

Abbreviations: Liso-cel, lisocabtagene maraleucel; TEAE, treatment-emergent adverse event.

*Multiple organ dysfunction syndrome caused by disease progression.

**Table 3** AEs of special interest and their management

| Parameter                        | Liso-cel-treated patients (N = 10) |
|----------------------------------|-----------------------------------|
| Patients with TEAEs, n (%)       |                                   |
| CRS (Lee 2014 criteria), 26       |                                   |
| All grades, n (%)                |                                   |
| Grade 1                          | 3 (30)                            |
| Grade 2                          | 2 (20)                            |
| Time to onset, median (range), days | 3 (2–9)                        |
| Time to resolution, median (range), days | 4 (1–5)                      |
| Grade ≥ 3 CRS n (%)              | 0                                 |
| NEs                              |                                   |
| All grades, n (%)                | 1 (10)                            |
| Grade 1                          | 1 (10)                            |
| Time to onset, days              | 4                                 |
| Time to resolution, days         | 3                                 |
| Grade ≥ 3, n (%)                 | 0                                 |
| Management of CRS and/or NEs, n (%) |                         |
| Tocilizumab only for CRS management | 2 (20)                        |
| Corticosteroids only for NEs management | 0                             |
| Tocilizumab and corticosteroids for concurrent CRS and NEs | 1 (10) |
| Prolonged cytopenia, 6 (60)      |                                   |

Abbreviations: AE, adverse event; CRS, cytokine release syndrome; liso-cel, lisocabtagene maraleucel; NE, neurological event; TEAE, treatment-emergent adverse event.

*Based on laboratory assessments of neutropenia, thrombocytopenia, or anemia of grade ≥ 3 not resolved by study day 29.
3.5 | B-cell aplasia

B-cell aplasia was evident at baseline in 80% \((n = 8/10)\) of patients. Post-infusion B-cell aplasia was reported in 100% of evaluable patients from study days 8 to 180 and in 50% of evaluable patients \((n = 1/2)\) by day 270 (Figure 4).

3.6 | Patients who received nonconforming CAR T-cell product

The 2 patients who received nonconforming CAR T-cell product both experienced neutropenia, anemia, leukopenia, and thrombocytopenia. One of these patients also experienced grade 2 diarrhea, grade 2 CRS, and grade 2 hypogammaglobulinemia; this patient achieved a CR, was alive at the data cutoff date, and had a PFS of 12.5 months from product infusion. The other patient experienced grade 1 vomiting and grade 1 fever, then later disease progression (PFS of 1 month from product infusion); the patient died about 2 months later.

3.7 | Patient narrative: secondary CNS lymphoma

One 53-year-old male patient with primary testicular DLBCL was diagnosed with secondary CNS lymphoma after screening but before liso-cel infusion. The patient had received three prior lines of therapy but relapsed with subcutaneous lesions within 2 months of the last line of therapy, as seen on gadolinium-enhanced MRI. After leukapheresis, the patient received gemcitabine as a bridging therapy that was effective in treating the subcutaneous lesions. Although the patient had no neurological or other symptoms, a brain parenchymal lesion was detected by contrast-enhanced CT scan during the pretreatment evaluation. Meningeal infiltration was not suspected, with negative cerebrospinal fluid. Subsequently, the patient received two cycles of high-dose methotrexate to prevent rapid progression of the brain mass lesion, with a response of stable disease (Figure 5A). Because he remained neurologically asymptomatic, the patient was considered eligible for treatment per protocol and the decision was made to proceed with liso-cel infusion.

Two days after infusion, the patient experienced grade 2 CRS, with symptoms of fever (temperature, 38.7°C) and hypotension (74/43 mm Hg) that responded to tocilizumab and hydration. The patient also experienced grade

| IRC-assessed response (Lugano 2014 criteria) | Liso-cel-treated patients \((N = 10)\) |
|---|---|
| ORR, \(n (%)\) | 7 (70) |
| CR | 5 (50) |
| PR | 2 (20) |
| SD | 0 |
| PD | 3 (30) |
| DOR, median (95% CI), months | 9.1 (2.1—NR) |
| PFS, median (95% CI), months | 6.3 (0.6—NR) |
| OS, median (95% CI), months | 14.7 (1.7—NR) |

Abbreviations: CI, confidence interval; CR, complete response; DOR, duration of response; IRC, independent review committee; liso-cel, lisocabtogene maraleucel; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
1 confusion and nausea on day 5. A CT scan showed a reduction of the CNS lesion; peritumoral cerebral edema was also observed, which may have been associated with an antitumor immune response (Figure 5B). Dexamethasone (20 mg/day every 6 h for 2 days and tapered) was administered to treat the cerebral edema. The patient experienced a rapid improvement in symptoms after the initiation of high-dose steroids and achieved a complete metabolic response by PET scan on day 29 (Figure 5C), which persisted for 3 months after infusion (Figure 5D). Despite exposure to high-dose steroids, liso-cel remained detectable 6 months after infusion. The patient achieved a CR per investigator assessment on days 29, 90, and 180, and progressive disease on day 270. Per IRC, the patient achieved a PR on days 29 and 90, a CR on day 180, and progressive disease on day 270.

4 | DISCUSSION

Cohort 3 of TRANSCEND WORLD is the first study to evaluate the clinical safety and efficacy profile of liso-cel in Japanese patients with R/R LBCL and is representative of most patients diagnosed with DLBCL in Japan with respect to histology, age, and general disease burden. This study allowed patients with secondary CNS lymphoma to be included, as well as bridging therapy while CAR T cells were being manufactured. After a 12.5-month median follow-up, rapid and durable efficacy, with a manageable safety profile, was demonstrated in this patient cohort. The ORR was 70% by IRC and median OS was nearly 15 months. Notably, CRS and NEs occurred at low rates, with no events reported as grade ≥3, and all events resolved rapidly. Most TEAEs were cytopenias, which was...
expected given the prior treatment and LDC. Infection and hypogammaglobulinemia rates were low.

Safety and efficacy outcomes in Cohort 3 were generally similar to those observed in the pivotal TRANSCEND NHL 001 LBCL study (N = 269) conducted in the United States. While direct comparison of outcomes is limited by the small sample size of TRANSCEND WORLD Cohort 3, naive comparisons indicated comparable ORR and CR rates (~70% and ~50%, respectively) for the two populations. Rates of all-grade CRS and NEs in Cohort 3, all of which were low grade, were also similar to the results from TRANSCEND NHL 001.

One patient in this cohort was diagnosed with secondary CNS lymphoma after screening but before liso-cel infusion and achieved a complete durable response. In the pivotal TRANSCEND NHL 001 study, there were six efficacy-evaluable patients with secondary CNS involvement, three of whom achieved a CR; none had severe CRS, and two patients experienced grade 3 NEs. Hypofibrinogenemia, which has been associated with CD19-directed CAR T-cell therapy in patients with LBCL, was observed at a higher rate in Cohort 3 than TRANSCEND NHL 001. However, no severe bleeding events were reported as a result of liso-cel treatment in this patient population.

Two patients experienced relapse after achieving a CR after liso-cel infusion. Because information on biopsy at relapse after liso-cel was not available at data cutoff, mechanisms of resistance in these patients are unclear. Mechanisms of relapse after CR with CAR T-cell therapy is not entirely understood and is an active area of interest. Hypotheses include exhaustion of CAR T cells, changes to the tumor microenvironment, and loss or modulation of CD19 target antigen. However, in a post hoc analysis of patients who had prior CD19-directed therapies before receiving liso-cel in TRANSCEND NHL 001, 92% achieved responses with no apparent effects on cellular kinetics. Additionally, a study of genomic mechanisms involved in resistance to CAR T-cell therapy in patients with LBCL found that neither reduced expression nor genomic alteration of CD19 was associated with poor outcomes.

Cellular kinetics and B-cell aplasia incidence in this cohort were also similar to those in the pivotal TRANSCEND NHL 001 study. No immunologic variables are expected to lead to a difference in product behavior between ethnicities, nor is the CD8⁺:CD4⁺ T-cell ratio expected to have a different impact in this population. There were no dose-limiting toxicities in this study, and efficacy and safety outcomes in Cohort 3 were aligned with TRANSCEND NHL 001. Although some drugs have demonstrated racial/ethnic differences in pharmacokinetics, no baseline intrinsic and disease factors have yet been identified that may impact CAR T-cell expansion or persistence among different ethnic groups. In the TRANSCEND NHL 001 study, higher liso-cel expansion was associated with response (CR or PR), but there were no apparent differences in cellular kinetics observed between responders and nonresponders in this cohort, likely due in part to the high variability of cellular kinetics and the limited number of patients. However, liso-cel showed long-term persistence. Preclinical evidence suggests this may be a benefit of 4-1BB-based CAR T-cell therapy.
Three second-generation anti-CD19 CAR T-cell therapies have demonstrated efficacy and safety in Japan for patients with R/R aggressive B-cell NHL: tisagenlecleucel,\textsuperscript{10} axicabtagene ciloleucel,\textsuperscript{9} and, with this report, liso-cel. Other CAR T-cell therapies did not permit enrollment of patients with secondary CNS lymphoma in their respective pivotal trials, but independent, retrospective, investigator-led studies have demonstrated that these patients can be successfully treated with CAR T-cell therapy.\textsuperscript{11,15,36–38} Based on these results, CAR T-cell therapies, including liso-cel, may represent a treatment option in selected patients with secondary CNS lymphoma. However, further evaluation is required to determine the exact role of CAR T-cell therapy in patients with CNS involvement. In addition, careful toxicity management, including brain edema, might be essential.

While other CAR T-cell therapies have been studied in Japanese patients, randomized trials comparing all three approved anti-CD19 CAR T-cell products are lacking. Actual differences in the safety and efficacy profiles of these products, therefore, remain unclear but may include differences in the CAR T-cell construct, manufacturing, and/or final infused CAR T-cell product. The Japanese subgroup analysis of tisagenlecleucel reported an ORR of 78\%, grade 3 or 4 CRS per the Penn grading system in two of nine patients (22\%), and grade 3 NEs in one of nine patients (11\%).\textsuperscript{10} In a study of axicabtagene ciloleucel in Japanese patients reporting an ORR of 87\%, grade 4 CRS per the Lee 2014 criteria occurred in one patient (6\%); no NEs were reported.\textsuperscript{9}

Despite the small number of patients and inherent limitations of the open-label, single-arm study design, it is encouraging that the results reported here align with the efficacy results observed in the much larger TRANSCEND NHL 001 study.\textsuperscript{6} Of note, our study enrolled a similar number of patients as were reported for other CD-19-directed CAR T-cell treatments in Japanese patients with R/R LBCL, with a longer follow-up time of 12.5 months (15 evaluable patients in the study of axicabtagene ciloleucel had a median follow-up time of 5.5 months\textsuperscript{9} and 9 infused patients for tisagenlecleucel had a median follow-up duration of 5.3 months for OS).\textsuperscript{10}

In conclusion, the majority of Japanese patients with R/R LBCL treated with liso-cel achieved a response by day 29, with a manageable safety profile. The IRC-assessed ORR was 70\%. In addition, 1 patient with secondary CNS lymphoma achieved a PR after liso-cel infusion per IRC that later deepened to a CR. CRS and NEs occurred at low rates, with no grade ≥3 events reported, and all events resolved. These data suggest that liso-cel appears to be a reasonable treatment option in Japanese patients with R/R LBCL.

**AUTHORS’ CONTRIBUTIONS**

Shinichi Makita: Data acquisition and data interpretation; Go Yamamoto: Data acquisition and data interpretation; Dai Maruyama: Data acquisition and data interpretation; Yuki Asano-Mori: Data acquisition and data interpretation; Daisuke Kaji: Data acquisition and data interpretation; Revathi Ananthakrishnan: Study conception or design, data analysis, and data interpretation; Ken Ogasawara: Data analysis, and data interpretation; Lara Stepan: Data analysis, and data interpretation; Claudia Schusterbauer: Study conception or design, data analysis, and data interpretation; Nils Rettby: Study conception or design, data analysis, and data interpretation; Jens Hasskarl: Study conception or design, data analysis, and data interpretation; Koji Izutsu: Data acquisition and data interpretation.

**ACKNOWLEDGMENTS**

This study was funded by Celgene, a Bristol-Myers Squibb Company. All authors, including employees of the sponsor, were involved in study design, the collection, and interpretation of the data, and writing and/or revising the manuscript. Authors had complete access to all study data and had final responsibility for the decision to submit for publication. All authors contributed to and approved the manuscript; writing and editorial assistance were provided by Jeremy Henrikes, PhD, of The Lockwood Group (Stamford, CT, USA), funded by Bristol Myers Squibb.

**CONFLICT OF INTEREST**

Shinichi Makita has received honoraria from Celgene, a Bristol-Myers Squibb Company, Chugai, Daiichi Sankyo, Eisai, Novartis, and Takeda. Go Yamamoto, Dai Maruyama, Yuki Asano-Mori, and Daisuke Kaji have no conflicts to report. Revathi Ananthakrishnan, Ken Ogasawara, and Lara Stepan are employees of Bristol Myers Squibb and may own stock in Bristol Myers Squibb. Jens Hasskarl was an employee of Celgene, a Bristol-Myers Squibb Company, at the time of this analysis and may own stock in Bristol Myers Squibb. Nils Rettby and Claudia Schusterbauer are employees of Celgene, a Bristol-Myers Squibb Company, and may own stock in Bristol Myers Squibb. Koji Izutsu has received research funding from Celgene, a Bristol-Myers Squibb Company.

**DATA AVAILABILITY STATEMENT**

Bristol Myers Squibb policy on data sharing may be found at [https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html](https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html).
ETHICS STATEMENT
The study adhered to the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from each patient. An independent ethics committee at each site reviewed and approved the protocol before initiating the study.

ORCID
Shinichi Makita https://orcid.org/0000-0001-6609-8088
Koji Izutsu https://orcid.org/0000-0002-4264-8927
Ken Ogawara’s https://orcid.org/0000-0002-4264-8927

REFERENCES
1. Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int. 2008;58:174-182.
2. Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan. Int J Hematol. 2018;107:420-427.
3. Gisselbrecht C, Van Den Neste E. How I manage patients. Haematol Int. 2018;32:63-643.
4. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma. Br J Haematol. 2018;182:633-643.
5. Suzuki T, Maruyama D, Maeshima AM, et al. Impact of the double expression of MYC and BCL2 on outcomes of primary refractory diffuse large B-cell lymphoma following R-CHOP chemotherapy. Blood. 2017;130:2846.
6. Abramson JS, Palomba ML, Gordon LI, et al. Liscatabagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839-852.
7. Makita S, Yoshimura K, Tobinai K. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. 2017;108:1109-1118.
8. Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688-1700.
9. Kato K, Makita S, Goto H, et al. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int J Clin Oncol. 2022;27:213-223.
10. Goto H, Makita S, Kato K, et al. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Int J Clin Oncol. 2020;25:1736-1743.
11. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31-42.
12. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439-448.
13. Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449-459.
14. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
15. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56.
16. Teoh J, Johnstone T, Christin B, et al. Liscatabagene maraleucel (liso-cell) manufacturing process control and robustness across CD19+ hematological malignancies. Blood. 2019;134(suppl 1):593.
17. Teoh J, Mallaney M, Hause RJ, Albertson T, Ramsborg CG, Larson RP. The liscatabagene maraleucel (liso-cell) manufacturing process is designed for consistency, purity, and robustness across B-cell malignancies. Mol Ther. 2020;28:31-32.
18. Teoh J, Charab W, Van Gunst K, et al. The manufacturing process for liscatabagene maraleucel (liso-cell) enables robust clearance of non-T cell impurities across B-cell malignancies. Mol Ther. 2021;29:410-411.
19. Sommermeyer D, Hudecek M, Kosash PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492-500.
20. Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.
21. Makita S, Imaizumi K, Kurosawa S, Tobinai K. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs Context. 2019;8:212567.
22. Zhao X, Yang J, Zhang X, et al. Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia. Mol Ther Oncolytics. 2020;18:272-281.
23. Abken H. Costimulation engages the gear in driving CARs. Immunity. 2016;44:214-216.
24. Ramsborg CG, Guptill P, Weber C, et al. JCAR017 is a defined composition CAR T cell product with product and process controls that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL. Blood. 2017;130:4471.
25. Cheson BD, Fisher RJ, Barrington SE, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-3068.
26. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.
27. Ogawara K, Dodds M, Mack T, Lymp J, Dell’Araga J, Smith J. Population cellular kinetics of Liscatabagene Maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory large B-cell lymphoma. Clin Pharmacokinet. 2021;60:1621-1633.
28. Hashmi H, Mirza A-S, Darwin A, et al. Hypofibrinogenemia in patients receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy for large B cell lymphoma: a single institution experience. Biol Blood Marrow Transplant. 2020;26:S257-S258.
29. Hashmi H, Mirza AS, Darwin A, et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020;4:4086-4090.
30. Johnsrud A, Craig J, Baird J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. *Blood Adv*. 2021;5:4465-4475.

31. Solomon SR, Mehta A, Abramson JS, et al. Experience of prior anti-CD19 therapy in patients (pts) with relapsed or refractory (R/R) large B-cell non-Hodgkin lymphoma (B-NHL) receiving Lisocabtagene Maraleucel (liso-cel), an investigational anti-CD19 chimeric antigen receptor (CAR) T cell product. *Transplant Cell Ther*. 2021;27:S207-S208.

32. Jain MD, Ziccheddu B, Coughlin CA, et al. Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy. *Blood*. 2021;138:42.

33. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. *Expert Opin Drug Metab Toxicol*. 2009;5:243-257.

34. Ramamoorthy A, Pacanowski M, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. *Clin Pharmacol Ther*. 2015;97:263-273.

35. Lu P, Lu X-a, Zhang X, et al. Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process. *J Clin Oncol*. 2018;36:3041.

36. Bennani NN, Maurer MJ, Nastoupil LJ, et al. Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium. *Blood*. 2019;134:763.

37. Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. *Blood*. 2019;134:860-866.

38. Novo M, Ruff MW, Skrabek PJ, Lin Y. Axicabtagene ciloleucel chimeric antigen receptor T cell therapy in lymphoma with secondary central nervous system involvement. *Mayo Clin Proc*. 2019;94:2361-2364.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher's website.

---

**How to cite this article:** Makita S, Yamamoto G, Maruyama D, et al. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Cancer Med*. 2022;11:4889-4899. doi: [10.1002/cam4.4820](https://doi.org/10.1002/cam4.4820)